The apolipoprotein E4 (APOE4) allele is associated with an early age of onset of the nonfamilial form of Alzheimer disease (AD) and with increased 8 protein amyloid deposition in the brain. These two observations may both arise from an effect of the apoE family of proteins on the rate of in vivo amyloidogenesis. We report here that apoE3, the common apoE isoform, is an in vitro amyloid nucleation inhibitor at physiological concentrations. A significant delay in the onset of amyloid fibril formation by the ,3-amyloid protein of AD (181-40) was observed at a low apoE3 concentration (40 nM), corresponding to an apoE3/13 protein molar ratio of 1:1000. The inhibitory activity of a proteolytic fragment of apoE3, containing the N-terminal 191 amino acids, is comparable to the native protein, whereas the C-terminal fragment has no activity. ApoE4 is equipotent or slightly less potent than apoE3, which may be due to its inability to form a disulfide dimer, since the apoE3 dimer is a significantly more potent nucleation inhibitor than apoE4. Neither apoE3 nor apoE4 inhibits the seeded growth of amyloid or affects the solubility or structure of the amyloid fibrils, indicating that apoE is not a thermodynamic amyloid inhibitor. We propose that the linkage between the APOE4 allele and AD reflects the reduced ability of APOE4 homozygotes to suppress in vivo amyloid formation.
protein of AD (181-40) was observed at a low apoE3 concentration (40 nM), corresponding to an apoE3/13 protein molar ratio of 1:1000. The inhibitory activity of a proteolytic fragment of apoE3, containing the N-terminal 191 amino acids, is comparable to the native protein, whereas the C-terminal fragment has no activity. ApoE4 is equipotent or slightly less potent than apoE3, which may be due to its inability to form a disulfide dimer, since the apoE3 dimer is a significantly more potent nucleation inhibitor than apoE4. Neither apoE3 nor apoE4 inhibits the seeded growth of amyloid or affects the solubility or structure of the amyloid fibrils, indicating that apoE is not a thermodynamic amyloid inhibitor. We propose that the linkage between the APOE4 allele and AD reflects the reduced ability of APOE4 homozygotes to suppress in vivo amyloid formation.
Amyloid plaque is an ordered, fibrous protein aggregate that is characteristic of the Alzheimer disease (AD) brain. The acceleration of amyloid deposition may be a primary event in AD (1, 2) . Thus, endogenous factors that affect the rate of amyloid formation could play a significant role in the pathogenesis of AD (3, 4) . The apolipoprotein E genotype (APOE) has recently been recognized as a susceptibility factor for AD (5) (6) (7) (8) . Three isoforms of apoE occur in the human population. They differ by single amino acid changes. APOE3 is the most common allele (0.78), followed by APOE4 (0.14) and APOE2 (0.07) (9) . ApoE4 and apoE3 differ with respect to lipoprotein binding (10) , but the two proteins are indistinguishable with respect to low density lipoprotein receptor binding (11) . ApoE3 and apoE4 are distinguished by a single point mutation in a sequence of 299 amino acids (apoE3, C112; apoE4, R112) (12) .
TheAPOE4 allele correlates with an earlier age of AD onset (5) and an increased amount of cerebral amyloid plaque (13) at the time of death relative to the common APOE3 allele. Exogenous seed fibrils will bypass the lag time and result in rapid growth that is not inhibited by apoE (see Fig. 2 ). associated with AD plaques in vivo (14, 15) and has been shown to bind to the circulating variant of the AD plaque protein family (131-40) in vitro (7, 16, 17) . It has been speculated that apoE4 may accelerate amyloid formation (15) . However, this proposal has not been experimentally tested.
The formation of a 1 protein amyloid fibril, like a crystallization, is rate limited by nucleation ( Fig. 1) (3, 4) . Nucleus formation involves a series of unfavorable protein association equilibria (K,, << 1) . Consequently, at a 13 protein concentration slightly above its solubility, a lag time is observed before aggregation occurs (4 tTo whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. of apoE3 were purified as detailed in the literature (18) . The apoE3 dimer was isolated as reported in the literature (19) . The molecular masses of these proteins and their purity were checked by SDS/PAGE under nonreducing conditions. The apoE3 and the apoE3 N-terminal domain samples contained a significant amount of dimer (10-30%). We thank J. Horowitz (University of California, Los Angeles) for the gift of a-crystallin (20) . Insulin was obtained from Sigma and bovine serum albumin was obtained from Pierce. The peptide apoE226-243 was synthesized on Rink Amide MBHA resin (Novabiochem), purified by reversed-phase high-pressure liquid chromatography, and characterized by plasma desorption mass spectrometry (M + H+ = 2197, calculated = 2193.2) and amino acid analysis.
Aggregation Assay: Turbidity. Stock solutions (unstirred) were prepared by dissolving ,B1-40 (Bachem) in dimethyl sulfoxide (DMSO) at 1-1.5 mM. The peptide solution was then sonicated for 30 min and filtered through Millex-FG 0.22-,um filters (Millipore). The final ,31-40 concentration was determined by quantitative amino acid analysis. Sonication and filtration were critical to remove any trace of undissolved seeds that may resist solubilization. In the absence of filtration, immediate nucleation was occasionally observed, presumably due to the undetected presence of undissolved seeds in the DMSO solution. Aliquots of 131-40 stock (40 nmol in =40 ,ul of DMSO) were added to aqueous buffer (1 ml total vol; 100 mM NaCl/10 mM NaH2PO4, pH 7.4). Aggregation was measured by turbidity at 400 nm vs. a buffer blank. The peptide solutions were briefly Vortex mixed before each absorbance measurement in order to evenly suspend the fibrils. For aggregation experiments with apoE, ,B1-40 stock (40 nmol in DMSO) was added to buffer containing 0.1% of a molar equivalent of apoE3 or apoE4. Absorbance (400 nm) was measured vs. a blank containing buffer and apoE. Stock solutions (stirred) were prepared as described for unstirred assays. Aliquots of l31-40 stock (80 nmol in DMSO) were 5000 10,000
Time, sec added to aqueous buffer (1 ml total vol) or to buffer containing 1% of a molar equivalent of apoE. (20) , at 10 times the concentration (400 nM), had no effect on the observed lag time. In addition, an 18-amino acid synthetic peptide based on a potential amphiphilic helix in apoE (apoE226-243) had no effect on amyloid formation at 5% of a molar equivalent (2 ,tM). Under these conditions, apoE3 at 1:100 (31-40 (400 nM) delayed nucleation beyond 30 days.
Amyloid formation by the 13 (21) , the lag time is extremely difficult to measure more accurately (4) . Consequently, the error in our measurement of nucleation time, whether by the turbidity assay or by a radioassay, was approximately equal to the difference between apoE3 and apoE4. An additional complication results from differences in nucleation time between commercial lots of ,31-40, possibly due to the presence of undetectable impurities (22) . Therefore, each experiment was done with a single 131-40 lot and only qualitative comparisons were made between experiments done with different lots (e.g., Fig. 2 vs. Fig. 3 ). These comparisons were based on the "normalization" of the data to the uninhibited (131-40 alone)
case.
The N-Terminal Domain of ApoE3 Contains the Inhibitory Function. Proteolysis of apoE3 by thrombin provides two fragments (23) . One is a 22-kDa N-terminal domain (residues 1-191), which contains the low density lipoprotein receptorbinding region and the site of the mutation that distinguishes apoE3 and apoE4 (apoE3 = C112; apoE4 = R112). The other is a 10-kDa C-terminal fragment (residues 215-291), which contains the lipoprotein binding function and controls tetramerization of apoE in solution (10, 24) . These two fragments were tested as aggregation inhibitors in the assay described above. The C-terminal fragment had no activity at 1% of a molar equivalent (800 nM); however, the N-terminal fragment was an effective nucleation inhibitor at that concentration (Fig.  3 Upper).
The ApoE3 Disulfide Dimer Is a Very Efficient Nucleation Inhibitor. Analysis of apoE3 and apoE4 by gel electrophoresis under nonreducing conditions indicated that apoE3 contained a small amount of disulfide dimer (10-30%) under the conditions of the aggregation assay. ApoE4 is unable to dimerize due to the C112R mutation. To test the possibility that dimerization was responsible for the slight difference in the inhibitory activities of the two variants, we tested the apoE3 covalent dimer (19) . The apoE3 dimer at 400 nM (0.5% of a molar equivalent based on 11-40; lag time = 605 + 50 min) was a much more potent inhibitor than apoE4 (lag time = 224 ± 100 min; Fig. 3 Lower) at twice the concentration. The unusual shape of the inhibited aggregation curve (i.e., slight increase in turbidity before rapid growth begins) suggests that the aggregation mechanism may be altered by the apoE3 dimer.
ApoE Does Not Inhibit Seeding or Affect the Stability or Structure of the Amyloid Fibrils. The insignificant effect of apoE on amyloid growth rate and final solubility in the kinetic assay suggested that apoE does not interfere with the postnucleation aggregation process. Consistent with that postulate, the presence of apoE3 or apoE4 (1%) had no effect on the seeding of amyloid formation by (31-40 fibrils (Fig. 2) (3) . Furthermore, at concentrations sufficient to significantly delay nucleation, neither apoE3 nor apoE4 had a measurable Finally, amyloid fibrils formed in the presence of inhibitory concentrations of apoE3 and apoE4 were indistinguishable from those formed in their absence, with regard to their morphology (electron microscopy; Fig. 4A ) and secondary structure (FTIR microscopy; Fig. 4B ).
DISCUSSION
The studies presented here demonstrate that in vitro nucleation of amyloid formation by l31-40 is inhibited by concentrations of apoE3 and apoE4, which are low in the relative (0.1% of a molar equivalent compared to ,81-40) and absolute (40 nM) senses. ApoE is known to be produced in the brain and a concentration of 100 nM has been measured in human cerebrospinal fluid (25) . This concentration of apoE is sufficient to delay the nucleation of amyloid in a physiologically significant way. The stoichiometry of inhibition of nucleation by apoE3 and apoE4 suggests that apoE binds to a prenucleus oligomeric intermediate (e.g., 13n-l; Fig. 1 ) and prevents its elaboration, as opposed to binding to monomeric ,B1-40. The fact that seeding of amyloid formation is not prevented by apoE3 or apoE4 is consistent with that scenario. Furthermore, inhibitory concentrations of apoE do not affect the growth, stability, or structure (Fig. 4) of ,B1-40 amyloid fibrils. Thus, apoE may not interact strongly with the amyloid nucleus or the subsequent intermediates (Fig. 1) .
The precision of the assay of amyloid formation used here was insufficient to distinguish the inhibitory activities of apoE3 and apoE4. However, the apoE3 disulfide dimer, which was present at low levels in the apoE3 sample, was a significantly more efficient nucleation inhibitor than apoE4 (Fig. 3 Lower). This effect may derive from the entropic benefit of tethering two (-oligomer binding domains. However, oligomerization of apoE does not always result in increased activity; deletion of the C-terminal domain, which mediates reversible apoE tetramerization in solution (24), does not significantly reduce the activity (Fig. 3 Upper) . The functionally significant interaction between apoE and the (3 protein oligomer involves the Nterminal domain of apoE (apoEl-191) (12) . The molecular basis of this effect is unknown.
The correlation of the APOE4 allele with an earlier age of AD onset (5) and an increased amount of amyloid at the time of death (13) has stimulated rampant speculation concerning the underlying molecular mechanism. It has been proposed that apoE4 may promote amyloid formation by stabilizing the aggregating conformation of the (3 protein (15) . However, we have proven that both common apoE variants inhibit amyloid formation. The demonstration that the C-terminal sequence is required for the rapid binding of apoE4 to (apoE3 binds more slowly) led to the several proposals featuring the apoE-( heterodimer (7) . However, the nucleation-inhibition activity reported here does not require the C-terminal domain of apoE and occurs at a stoichiometry that rules out the heterodimer as a relevant species.
We propose that amyloidogenesis occurs at a low rate in most individuals, due, in part, to the suppression of nucleation of amyloid formation by endogenous apoE. Inefficient suppression of amyloid formation by anAPOE4 homozygote could be a contributing factor to the development of AD. The in vivo crystallizations of calcium oxalate [from supersaturated urine (26) ] and of calcium phosphate [from supersaturated saliva (27) ] are also suppressed by endogenous inhibitor proteins. The apoE3 dimer is clearly a more efficient nucleation inhibitor than apoE4, which cannot dimerize. The plasma dimer levels forAPOE3 homozygotes average -27% of total apoE3, which is sufficient to explain more efficient amyloid suppression in these individuals (19) . The wide range in reported dimer levels (12-37%) suggests that factors that alter the apoE3 monomer/dimer ratio may also be important in AD pathogenesis. In addition, the plasma apoE4 concentration of an APOE4 homozygote is '40% lower than the plasma total apoE3 concentration in an APOE3 homozygote (-1.5 mM) (28) . The analogous measurement of cerebrospinal fluid or brain tissue has not been reported, but if a comparable concentration difference exists in the brain it could partly or fully explain the compromised ability ofAPOE4 homozygotes to suppress amyloidogenesis. Finally, the correlation between APOE genotype and AD risk may also involve events other than amyloidogenesis (29) .
The findings reported here have significant practical implications. Transgenic apoE "knockout" mice in which the ,3-amyloid precursor protein (APP) is overexpressed could be excellent models for AD amyloidogenesis, since their natural amyloid suppression system is compromised. Recent attempts to construct transgenic mice that overexpress apoE4 and APP may have been misguided by the incorrect assumption that apoE4 promotes amyloid formation (30) . It has been observed that low concentrations of apoE attenuate the neurotoxicity of ,B protein (31) . This effect may be due to inhibition of amyloid nucleation by apoE, an activity that may have therapeutic benefit. Prenucleus oligomers represent the most efficient target for endogenous amyloid inhibitors since they are sparsely populated during the aggregation process (4) and the inhibitor protein need only be expressed at trace levels. Synthetic, nonpeptide inhibitors could be designed to follow nature's strategy by "poisoning" the crystallization of amyloid (22) .
